Exonate

Exonate is a company focused on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases with highly unmet medical needs. Alternative mRNA splicing is regulated in disease states, leading to pathological blood vessel formation (angiogenesis), a key driver in the progression of ocular diseases and cancer. The founders of Exonate have identified and generated a new class of drugs, "SPHINXes," which modulate alternative mRNA splicing. The company has developed a series of molecules that can provide therapeutic options for anti-angiogenic therapies in ophthalmology, oncology, analgesia, diabetes, neurodegenerative diseases, and renal diseases.